TABLE 3.
Demographic and Clinical Characteristics of HIV-Infected Adults and Adolescents Who Were Currently Receiving HIV Care by ART* Use, Kenya AIDS Indicator Survey 2012
| Total in HIV Care†
|
Currently on ART Unweighted, N = 240‡
|
Not on ART Unweighted, N = 86§
|
||||||
|---|---|---|---|---|---|---|---|---|
| Variable | Unweighted, N† | Unweighted, n | Weighted % | 95% CI | Unweighted, n | Weighted % | 95% CI | P |
| Total | 326 | |||||||
| Sex | 0.2683 | |||||||
| Men | 79 | 61 | 31.9 | 25.7 to 38.0 | 18 | 25.3 | 15.7 to 34.8 | |
| Women | 247 | 179 | 68.1 | 62.0 to 74.3 | 68 | 74.7 | 65.2 to 84.3 | |
| Age group, yrs | <0.0001 | |||||||
| 15–29 | 62 | 37 | 14.3 | 9.9 to 18.6 | 25 | 30.6 | 20.0 to 41.2 | |
| 30–39 | 116 | 79 | 30.7 | 24.5 to 36.9 | 37 | 42.8 | 32.8 to 52.9 | |
| 40–49 | 89 | 73 | 33.6 | 26.7 to 40.5 | 16 | 18.7 | 9.4 to 28.0 | |
| 50 and above | 59 | 51 | 21.4 | 15.6 to 27.2 | 8 | 7.9 | 2.4 to 13.4 | |
| Marital status | 0.9198 | |||||||
| Ever widowed | 76 | 59 | 22.4 | 16.3 to 28.6 | 17 | 20.3 | 10.1 to 30.4 | |
| Married/cohabiting | 189 | 138 | 60.4 | 52.4 to 68.4 | 51 | 62.4 | 50.5 to 74.4 | |
| Other | 61 | 43 | 17.1 | 12.1 to 22.2 | 18 | 17.3 | 9.2 to 25.4 | |
| Highest educational attainment | 0.1295 | |||||||
| Primary or less | 143 | 103 | 40.4 | 32.9 to 48.0 | 40 | 43.7 | 33.6 to 53.9 | |
| Secondary/vocational | 75 | 52 | 21.5 | 15.1 to 27.9 | 23 | 30.2 | 19.4 to 41.0 | |
| College | 108 | 85 | 38.1 | 29.7 to 46.4 | 23 | 26.1 | 16.6 to 35.6 | |
| Employed | 0.3576 | |||||||
| Yes | 204 | 145 | 61.7 | 54.8 to 68.5 | 59 | 67.7 | 56.7 to 78.8 | |
| No | 122 | 95 | 38.3 | 31.5 to 45.2 | 27 | 32.3 | 21.2 to 43.3 | |
| Region | 0.5958 | |||||||
| Nairobi | 35 | 25 | 8.6 | 6.1 to 11.0 | 10 | 9.0 | 3.8 to 14.3 | |
| Central | 30 | 24 | 9.5 | 5.8 to 13.1 | 6 | 6.3 | 2.1 to 10.6 | |
| Coast | 29 | 21 | 5.9 | 4.1 to 7.7 | 8 | 8.5 | 2.2 to 14.8 | |
| Eastern | 36 | 31 | 11.7 | 7.3 to 16.0 | 5 | 6.0 | 0.6 to 11.4 | |
| Nyanza | 134 | 97 | 40.3 | 32.2 to 48.4 | 37 | 43.8 | 29.6 to 58.0 | |
| Rift Valley | 28 | 21 | 14.4 | 7.6 to 21.1 | 7 | 11.8 | 3.4 to 18.1 | |
| Western | 34 | 21 | 9.8 | 4.0 to 15.5 | 13 | 14.5 | 6.2 to 22.7 | |
| Residence | 0.8803 | |||||||
| Rural | 191 | 140 | 60.5 | 52.8 to 68.1 | 51 | 59.4 | 45.8 to 73.0 | |
| Urban | 135 | 100 | 39.5 | 31.9 to 47.2 | 35 | 40.6 | 27.0 to 54.2 | |
| Wealth index | 0.6592 | |||||||
| Poorest | 45 | 36 | 16.4 | 10.0 to 22.8 | 9 | 9.2 | 2.7 to 15.8 | |
| Second | 84 | 59 | 25.9 | 17.4 to 34.5 | 25 | 29.5 | 17.7 to 41.3 | |
| Third | 77 | 56 | 24.4 | 17.3 to 31.5 | 21 | 25.7 | 16.2 to 35.2 | |
| Fourth | 73 | 55 | 19.6 | 12.9 to 26.3 | 18 | 21.9 | 11.4 to 32.4 | |
| Richest | 47 | 34 | 13.7 | 8.1 to 19.2 | 13 | 13.7 | 6.3 to 21.1 | |
| Time from diagnosis to care, months | 0.6398 | |||||||
| 3 or less | 204 | 149 | 82.1 | 75.4 to 88.7 | 55 | 79.2 | 70.0 to 88.4 | |
| More than 3 | 48 | 34 | 17.9 | 11.3 to 24.6 | 14 | 20.8 | 11.6 to 30.0 | |
| Time since last clinic visit, months | 0.0065 | |||||||
| 3 or less | 272 | 210 | 87.2 | 82.4 to 92.1 | 62 | 71.9 | 60.9 to 82.9 | |
| More than 3 | 53 | 29 | 12.8 | 7.9 to 17.6 | 24 | 28.1 | 17.1 to 39.1 | |
| Current use of cotrimoxazole | 0.0004 | |||||||
| Yes | 314 | 236 | 98.6 | 97.1 to 100 | 78 | 89.5 | 82.5 to 96.5 | |
| No | 11 | 3 | 1.4 | 0 to 2.9 | 8 | 10.5 | 3.5 to 17.5 | |
| Ever had CD4+ T-cell count measurement | 0.0076 | |||||||
| Yes | 286 | 222 | 90.0 | 82.8 to 97.3 | 64 | 72.9 | 64.0 to 81.9 | |
| No | 40 | 18 | 10.0 | 2.7 to 17.2 | 22 | 27.1 | 18.1 to 36.0 | |
| CD4+ T-cell counts, cells/μL¶ | 0.3876 | |||||||
| ≤ 350 | 43 | 35 | 35.2 | 23.8 to 46.7 | 8 | 23.2 | 6.8 to 39.7 | |
| 351–500 | 20 | 14 | 16.2 | 6.2 to 26.2 | 6 | 15.7 | 2.6 to 28.8 | |
| >500 | 84 | 60 | 48.6 | 35.2 to 62.0 | 24 | 62.4 | 43.7 to 81.1 | |
| HIV RNA concentration, copies/mL# | <0.0001 | |||||||
| <1000 | 168 | 146 | 75.3 | 68.7 to 81.9 | 22 | 30.2 | 20.7 to 39.6 | |
| ≥1000 | 97 | 48 | 24.7 | 18.1 to 31.3 | 49 | 69.8 | 60.4 to 79.3 | |
*
ART, antiretroviral therapy.
†
Because of missing responses totals vary between variables.
‡
Weighted percentage of persons in care who were receiving ART: 74.6% (95% CI: 69.0 to 80.2).
§
Includes 12 participants who were currently in care and had initiated but later discontinued ART.
¶
Excludes 179 specimens that could not be tested.
#
Excludes 61 specimens that could not be tested.